Ultragenyx Pharmaceutical Inc.
RARE
$39.34
$0.090.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.17% | 12.01% | 18.82% | 14.70% | 14.25% |
| Total Depreciation and Amortization | 36.67% | 52.48% | 63.55% | 52.91% | 42.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.73% | -26.55% | -53.66% | -56.23% | -51.34% |
| Change in Net Operating Assets | 192.17% | 168.19% | -283.91% | -197.60% | -125.07% |
| Cash from Operations | 12.77% | 13.02% | -2.34% | -21.17% | -24.80% |
| Capital Expenditure | 83.08% | 87.88% | 88.57% | 79.40% | 61.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.84% | -226.87% | 177.33% | 323.23% | 311.20% |
| Cash from Investing | -110.58% | -320.00% | 191.48% | 205.70% | 157.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.05% | 1,108.28% | 1,992.38% | 4,185.38% | 3,489.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 25,100.00% | 4,861.90% | -100.00% | -99.87% | -100.01% |
| Cash from Financing | 2.86% | 1,123.05% | 40.81% | -22.06% | -22.56% |
| Foreign Exchange rate Adjustments | -646.54% | 47.82% | -371.68% | 43.39% | 142.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.08% | 125.69% | 795.02% | 147.69% | 147.56% |
